Novartis submits meningococcal vaccine Bexsero for European approval
December 23, 2010Sales and Marketing Bexsero, MenB, Novartis, Vaccine, bacterial meningitis, bloodstream infection sepsis, meningococcal disease, meningococcal vaccine
Novartis has submitted its meningococcal vaccine Bexsero to European regulators for marketing approval. If approved the drug will be the …
2010: Pharma’s year in review
December 23, 2010Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2010, Avandia, China, European healthcare spending, GSK, Obama, year in review
2010 saw a harsh new economic reality dominate decisions in the US and Europe, but pharma seized on opportunities in …
PCTs look to save millions with new cuts
December 23, 2010Sales and Marketing GP consortia, NHS, NHS cuts, NHS reforms, PCTs, generic prescribing
The NHS in England is cutting back on so-called ‘low priority’ procedures and looking to increase generic prescribing in order …
Gilead set to acquire Arresto for $225 million
December 23, 2010Research and Development AB0024, Arresto, Cancer, Gilead, advanced solid tumours, ambrisentan, fibrotic diseases, idiopathic pulmonary fibrosis
Gilead Sciences is set to acquire fellow California, US-based biotech Arresto for $225 million to bolster its early stage pipeline. …
Service Insight: New year, new resolution and priorities for 2011
December 23, 2010Medical Communications Jo Spadaccino, Pegasus PR, Service Insight, Talking Point
SERVICE INSIGHTNow the nights have drawn in and as Christmas music drives this writer to distraction, my attention has been …
Digital Pharma: FDA delays social media guidance until 2011
December 22, 2010Medical Communications Digital Pharma blog, FDA, social media
The FDA will release its hotly-anticipated social media guidance for pharma companies in a piecemeal fashion, beginning in the first …
AstraZeneca takes $445m hit to halt motavizumab
December 22, 2010Research and Development AZ, AstraZeneca, MedImmune, motavizumab, respiratory, respiratory syncytial virus
AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the …
Novartis blood cancer drug impresses in late stage trial
December 22, 2010Research and Development, Sales and Marketing INC424, Novartis, blood cancer, myelofibrosis, orphan drug
Novartis has released positive phase III results of its myelofibrosis drug INC424 showing it met its primary endpoint of reducing …
Novo to develop oral insulin
December 22, 2010Research and Development Emisphere, Novo Nordisk, diabetes, insulin, oral insulin, type I diabetes
Novo Nordisk is to develop an oral formulation of insulin with US biotech company Emisphere Technologies. The New Jersey-based biotech …
BMS licences phase II HIV compound festinavir
December 22, 2010Research and Development BMS, Bristol-Myers Squibb, HIV, NRTI, Oncolys BioPharma, festinavir, nucleoside reverse transcriptase inhibitor
Bristol-Myers Squibb is to pay hundreds of millions of dollars to a Japanese biotech firm to get its hands on …
Liberating the NHS … whether it likes it or not
December 22, 2010Sales and Marketing GP consortia, NHS, NHS board, NHS reforms, value-based pricing
When health secretary Andrew Lansley announced plans in July to abolish the management structure of England’s health service, and hand …
AstraZeneca appoints Esra Erkal Paler head of global media relations
December 22, 2010Medical Communications AstraZeneca, Esra Erkal Paler, appointment, medical communications
AstraZeneca has appointed Esra Erkal Paler to head up its worldwide media relations activities. She will lead the company’s London-based …
Roche to challenge FDA on Avastin
December 21, 2010Sales and Marketing EMA, FDA, Roche, avastin, bevacizumab, breast cancer
Roche is set to challenge the decision by the FDA to remove a breast cancer indication from its blockbuster drug …
Novartis makes $500m investment in Russia
December 21, 2010Manufacturing and Production, Research and Development Novartis, Russia, pharma manufacturing
Novartis is planning to invest $500 million in Russia over the next five years, in a programme which will include …
Pharma manufacturing news in brief
December 21, 2010Manufacturing and Production Airgas, Anthera Pharmaceuticals, Avid Bioservices, Berlin Packaging, Continental Packaging Solutions, Inno Biologics, Janssen, Merck BioManufacturing Network, Shandong Yanggu Zhongshi Pharmaceutical, SurModics
Our round-up of manufacturing updates includes a European recall for J&J, new contract manufacturing awards and facility updates from around …
NHS framework outlines GP consortia assessment plans
December 21, 2010GP consortia, NHS, NHS Commissioning Board, NHS Outcomes Framework, NHS reform
The government has published details of how the new GP-led consortia, which will commission health services in the future, will …
Biogen Idec buys neurodegenerative disease rights
December 21, 2010Research and Development Alzheimer's, Alzheimer's disease, Alzheimer’s, Alzheimer’s disease, Biogen, Biogen IDEC, Neurimmune, Parkinson's disease, Parkinson’s disease, amyotrophic lateral sclerosis, neurodegenerative diseases
Biogen Idec has acquired a subsidiary of Swiss biotech company Neurimmune, and the rights to three pre-clinical immunotherapy drugs. The …
Congressman says FDA should scrutinise J&J’s manufacturing partners
December 21, 2010Manufacturing and Production BestSweet, FDA, J&J, JJ, Johnson & Johnson, McNeil, Rolaids, manufacturing compliance, recalls
The latest flurry of recalls from Johnson & Johnson has prompted additional calls for a wide-ranging investigation of the company’s …
Scottish First Minister seeks talks with Aptuit over plant closures
December 21, 2010Manufacturing and Production Aptuit, Scotland, manufacturing facilities, pharma manufacturing
US contract manufacturing and drug development company Aptuit says it may shut down two facilities in Lothian, Scotland, because demand …
CRM and software-as-a-service
December 21, 2010Sales and Marketing CRM, Dan Goldsmith, Service Insight, Veeva Systems
Service Insight from Dan Goldsmith, general manager, Europe, Veeva SystemsCriminal mastermind, Frank Abagnale Jr. (1901-1980), successfully conned millions of dollars …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
